GlassScriptPhysician profile
Stanley Schinke
NPI 1649277088
$20,865.94
in general payments reported to CMS, 2019-2025
85 companies · $3,807 in 2025
The $3,807 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,481 · 2020: $1,100 · 2021: $2,169 · 2022: $3,427 · 2023: $3,376 · 2024: $3,506 · 2025: $3,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,635 · Long Term Medical Supply Or Device Loan: $565 · Education: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,634.55 |
| Long Term Medical Supply Or Device Loan | $565.46 |
| Education | $489.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,746.85 | 2019-2025 | |
| Janssen Biotech, INC. | $1,771.95 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,342.80 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $1,267.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,042.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $992.58 | 2019-2025 | Opdualag, Opdivo, Reblozyl |
| Astellas Pharma US INC | $699.66 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Seagen INC. | $527.41 | 2019-2023 | Adcetris, Tivdak, Padcev |
| Amgen INC. | $503.43 | 2019-2025 | Lumakras, Blincyto, Kyprolis |
| Eisai INC. | $461.13 | 2019-2025 | |
| Celgene Corporation | $460.35 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $432.34 | 2019-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $416.56 | 2021-2025 | Ultomiris |
| Genzyme Corporation | $416.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.72 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $384.90 | 2019-2025 | Itovebi, Phesgo, Lunsumio |
| Daiichi Sankyo INC. | $360.68 | 2019-2025 | Injectafer, Enhertu, Vanflyta |
| Karyopharm Therapeutics INC. | $337.85 | 2022-2025 | Xpovio |
| Teva Pharmaceuticals USA, INC. | $333.03 | 2019-2020 | |
| Incyte Corporation | $321.94 | 2019-2025 | Jakafi, Monjuvi |
| Gilead Sciences, INC. | $258.45 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $249.38 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $247.67 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $242.79 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.29 | 2021-2025 | Libtayo |
| Array Biopharma INC | $234.80 | 2021-2025 | Mektovi, Braftovi, Tukysa |
| Emd Serono, INC. | $228.90 | 2019-2025 | Bavencio |
| Glaxosmithkline, LLC. | $210.41 | 2020-2024 | Shingrix, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $190.31 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $186.55 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Blueprint Medicines Corporation | $186.32 | 2021-2024 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $184.31 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Coherus Oncology, INC. | $184.00 | 2020-2023 | |
| Beigene USA, INC. | $177.46 | 2020-2025 | Tevimbra, Brukinsa |
| Stemline Therapeutics INC. | $148.87 | 2019-2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.30 | 2019-2025 | |
| Verastem, INC. | $127.26 | 2019 | |
| Kite Pharma, INC. | $113.20 | 2022-2025 | Yescarta |
| Exelixis INC. | $109.08 | 2019-2024 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $102.57 | 2022-2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $98.51 | 2022-2025 | |
| Sobi, INC | $96.92 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $93.43 | 2019-2024 | Provenge |
| Adaptive Biotechnologies Corporation | $92.82 | 2022-2023 | Clonoseq |
| Mirati Therapeutics, INC. | $85.19 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $82.05 | 2021-2023 | Fotivda |
| Myovant Sciences INC. | $69.37 | 2021-2022 | |
| Mylan Institutional INC. | $69.36 | 2019-2022 | |
| Foundation Medicine, INC. | $67.63 | 2019-2023 | |
| Taiho Oncology, INC. | $67.59 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $66.87 | 2021-2023 | Qinlock |
| Fennec Pharmaceuticals, INC. | $61.38 | 2025 | Fyarro |
| Pharmaessentia USA Corporation | $58.97 | 2025 | Besremi |
| Janssen Pharmaceuticals, INC | $49.65 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $46.64 | 2019-2022 | |
| Springworks Therapeutics, INC. | $44.99 | 2024 | Ogsiveo |
| Verity Pharmaceuticals INC. | $44.53 | 2023 | Trelstar |
| Tersera Therapeutics LLC | $43.58 | 2019 | |
| Spectrum Pharmaceuticals INC. | $41.00 | 2025 | Rolvedon |
| Helsinn Therapeutics (U.S.), INC. | $35.42 | 2019 | |
| Octapharma USA, INC. | $35.09 | 2024 | Octagam Immune Globulin (Human) |
| Tesaro, INC. | $35.04 | 2019 | |
| Immunocore Limited | $32.88 | 2024 | Kimmtrak |
| Csl Behring | $30.64 | 2019-2020 | |
| Partner Therapeutics, INC. | $29.87 | 2019-2020 | |
| Telix Pharmaceuticals | $27.60 | 2022-2023 | Illuccix |
| Beone Medicines USA, INC. | $26.10 | 2025 | Brukinsa |
| Genmab U.S., INC. | $25.12 | 2025 | Epkinly |
| Morphosys, US INC. | $24.85 | 2024 | Monjuvi |
| Epizyme, INC. | $23.84 | 2021 | |
| Agios Pharmaceuticals, INC. | $23.75 | 2025 | Pyrukynd |
| Grifols USA, LLC | $23.34 | 2019 | |
| Geron Corporation | $20.67 | 2025 | Rytelo |
| Dova Pharmaceuticals | $20.30 | 2021 | |
| Secura Bio, INC. | $19.89 | 2020 | |
| Servier Pharmaceuticals LLC | $19.65 | 2023 | |
| Clovis Oncology, INC. | $18.89 | 2019 | |
| Organon LLC | $18.73 | 2022 | |
| Kyowa Kirin, INC. | $18.49 | 2019 | |
| West Therapeutics Development, LLC | $17.83 | 2019 | |
| Acrotech Biopharma INC. | $17.62 | 2024 | Beleodaq |
| Aptevo Therapeutics INC | $17.20 | 2019 | |
| Myriad Genetic Laboratories, INC. | $15.82 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.88 | 2025 | Danziten, Vivimusta |
| Mayne Pharma Commercial LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
Kisqali $888Keytruda $687Lynparza $445Xtandi $352Darzalex $318Adcetris $316Lenvima $310Calquence $268Tecvayli $264Tukysa $261Scemblix $255Opdualag $249Imbruvica $246Elrexfio $237Reblozyl $230Xpovio $214Welireg $211Sarclisa $207Ultomiris $204Erleada $201Mektovi $188Piqray $187Braftovi $184Libtayo $161Talvey $157Orgovyx $156Ibrance $153Epkinly $140Imfinzi $130Rybrevant $124Ayvakit $123Opdivo $120Talzenna $120Bosulif $116Injectafer $116Padcev $114Jaypirca $108Lutathera $103Nubeqa $99.30Tavalisse $99.20Rezlidhia $99.20Onivyde $95.92Enhertu $92.77Brukinsa $88.72Udenyca $87.70Verzenio $86.52Fabhalta $86.16Elahere $85.91Krazati $85.19Venclexta $81.61Monoferric $79.80Vanflyta $78.21Tagrisso $74.37Ninlaro $68.93Tivdak $67.43Tevimbra $65.62Nerlynx $64.78Alunbrig $63.17Fruzaqla $62.34Fyarro $61.38Provenge $59.26Besremi $58.97Pluvicto $56.50Itovebi $56.01Lumakras $55.22Cabometyx $54.88Retevmo $53.83Paxlovid $53.68Comirnaty $53.68Phesgo $52.65Doptelet $52.10Orserdu $50.51Xofigo $49.89Polivy $49.79Lunsumio $49.79Zepzelca $49.53Ogsiveo $44.99Trelstar $44.53Clonoseq $44.01Jakafi $43.11Monjuvi $42.71Yescarta $41.61Rolvedon $41.00Gavreto $40.06Trodelvy $38.31Somatuline Depot $35.18Octagam Immune Globulin (Human) $35.09Kimmtrak $32.88Vyloy $31.61Kadcyla $30.41Rozlytrek $30.41Lonsurf $30.41Alecensa $30.41Inqovi $30.41Tecentriq $30.41Pomalyst $30.20Akeega $28.16Balversa $28.16Illuccix $27.24Columvi $26.28
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Schinke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.